CHARLOTTE CUNNINGHAM-RUNDLES, M.D., Ph.D.; FREDERICK P. SIEGAL, M.D.; ELIZABETH M. SMITHWICK, M.D.; ALISE LION-BOULÉ, R.N.; SUSANNA CUNNINGHAM-RUNDLES, Ph.D.; JOSEPH O'MALLEY, M.D.; SILVIO BARANDUN, M.D.; ROBERT A. GOOD, M.D., Ph.D.
Twenty-one patients with primary humoral immunodeficiency were treated for 1 year with a chemically intact immunoglobulin, 300 mg/kg body weight given intravenously every 3 weeks, to compare immunoglobulin levels and clinical status with results achieved after standard treatment with intramuscular immunoglobulin given previously for 1 year. A substantial reduction of specific acute illnesses and antibiotic use was found for 18 of the 21 patients, particularly during the second 6 months of treatment. Average IgG levels before intravenous infusion were increased 243 mg/dL over previous intramuscular pre-injection levels. Adverse effects were recorded for 2.5% of infusions.
Learn more about subscription options.
Register Now for a free account.
CUNNINGHAM-RUNDLES C, SIEGAL FP, SMITHWICK EM, LION-BOULÉ A, CUNNINGHAM-RUNDLES S, O'MALLEY J, et al. Efficacy of Intravenous Immunoglobulin in Primary Humoral Immunodeficiency Disease. Ann Intern Med. 1984;101:435-439. doi: 10.7326/0003-4819-101-4-435
Download citation file:
Published: Ann Intern Med. 1984;101(4):435-439.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only